Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1
(Source: Drugs)
Source: Drugs - March 15, 2024 Category: Drugs & Pharmacology Source Type: research
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
AbstractTamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to a broad spectrum of adverse effects, contributing to high discontinuation rates. Dose reductions of tamoxifen might be an option to reduce treatment-related toxicity, but large randomized controlled trials investigating the tolerability and, more importantly, efficacy of low-dose tamoxifen in the adjuvant setting are lacking. We conducted an extensive literature search ...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
AbstractCurrently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regardin...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
ConclusionsThe results of the comprehensive analysis suggested hypoglycemic drug therapy as an effective intervention for NAFLD, with or without diabetes mellitus. A prioritized selection of TZDs, vitamin E plus pioglitazone, GLP-1 receptor agonists and FGF-21 analogue may be considered for NASH resolution. Obeticholic acid, lanifibranor and silymarin could be considered for the improvement of liver fibrosis. Each medication was relatively safe compared with placebo. (Source: Drugs)
Source: Drugs - March 13, 2024 Category: Drugs & Pharmacology Source Type: research
Fidanacogene Elaparvovec: First Approval
This article summarizes the milestones in the development of fidanacogene elaparvovec leading to this first approval for moderately severe to severe (factor IX activity ≤ 2%) haemophilia B who are negative for neutralizing antibodies to AAVRh74var. (Source: Drugs)
Source: Drugs - March 12, 2024 Category: Drugs & Pharmacology Source Type: research
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
DiscussionIntravenous morphine likely offers benefits, but oral opioids may not provide clinically meaningful benefits.PROSPERO registrationCRD42021249346. (Source: Drugs)
Source: Drugs - March 7, 2024 Category: Drugs & Pharmacology Source Type: research
Adult-Onset Still ’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
AbstractAdult-onset Still ’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adu lts...
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Aponermin: First Approval
This article summarizes the milestones in the development of aponermin leading to this first approval for relapsed or refractory multiple myeloma. (Source: Drugs)
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
SER-109 (VOWST ™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
AbstractSER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recurrence ofClostridioides difficile infection (CDI) in patients 18 years of age and older following standard of care (SOC) antibacterial treatment for recurrent CDI. It is a purified bacterial spore suspension sourced from healthy donors. As the first oral faecal microbiota product approved for prevention of recurrent CDI, SER-109 is administered as four capsules once daily for three consecutive days. In a well-designed, placebo-controlled, phase III trial (ECOSPOR III), SER-109 significantly reduc...
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Adult-Onset Still ’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
AbstractAdult-onset Still ’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adu lts...
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Aponermin: First Approval
This article summarizes the milestones in the development of aponermin leading to this first approval for relapsed or refractory multiple myeloma. (Source: Drugs)
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
SER-109 (VOWST ™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
AbstractSER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recurrence ofClostridioides difficile infection (CDI) in patients 18 years of age and older following standard of care (SOC) antibacterial treatment for recurrent CDI. It is a purified bacterial spore suspension sourced from healthy donors. As the first oral faecal microbiota product approved for prevention of recurrent CDI, SER-109 is administered as four capsules once daily for three consecutive days. In a well-designed, placebo-controlled, phase III trial (ECOSPOR III), SER-109 significantly reduc...
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape
AbstractRosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients ’ quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment l andscape for rosacea management, as it is not yet included in clinical guidelines that predominant...
Source: Drugs - February 29, 2024 Category: Drugs & Pharmacology Source Type: research
Apadamtase Alfa: First Approval
This article summarizes the milestones in the development of apadamtase alfa leading to this first approval in the USA for congenital TTP. (Source: Drugs)
Source: Drugs - February 29, 2024 Category: Drugs & Pharmacology Source Type: research